The number of new antibiotics being approved by the US Food and Drug Administration (FDA) has steadily fallen over the years. As well as an R&D slowdown, a number of companies have backed out of the space to focus on other therapeutic areas, most recently Novartis.
In light of this, the FDA announced at the end of last week, and continued its coverage over the weekend on social media, that it would be identifying new ways to encourage drug development in the space.
in-PharmaTechnologist looks at how the risk of AMR has been viewed in the past, what the situation today is and how it could develop into the future.
